A lot hinges on continued growth to justify the high cash burn rate. The fear requiring additional capital will seriously depress the share price if they cannot show they are managing it well. They'll need to do it for more than one or two quarters to restore confidence.
If you believe in management and don't mind the risks of dilution, weak IP protection from competitors, there may be a buying opportunity, but imo I am not so sure it's cheap given the risk.
- Forums
- ASX - By Stock
- AVH on NASDAQ
A lot hinges on continued growth to justify the high cash burn...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M |
Open | High | Low | Value | Volume |
$2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 980 | $2.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 10173 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 980 | 2.740 |
3 | 36189 | 2.700 |
1 | 10000 | 2.680 |
3 | 2022 | 2.630 |
1 | 2671 | 2.620 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 10173 | 2 |
2.770 | 17029 | 3 |
2.780 | 1500 | 1 |
2.790 | 3162 | 1 |
2.800 | 2372 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online